Clinical and Tonometric Evaluation of Intravitreal Uveal Ablation with Gentamicin in Chronic Glaucomatous Dogs
World Small Animal Veterinary Association World Congress Proceedings, 2005
J.L.V. Chiurciu; C.V.S. Brandão; J.J.T. Ranzani; D.N. Cremonini
Faculdade de Medicina Veterinária e Zootecnia, Universidade Estadual Paulista-UNESP. Distrito de Rubião Jr. s/n, Botucatu, São Paulo, Brasil

Introduction: The purpose was to investigate the clinical and tonometric alterations in glaucomatous dogs treated with intravitreal uveal ablation.

Material and Methods: It was evaluated 13 canine eyes of dogs who were examined on the Ophthalmology Service of Veterinary Hospital in the University of Veterinary Medicine and Animal Science-UNESP-Botucatu, presenting unilateral chronic glaucoma with irreversible blindness. After general anesthesia, the sick eyes of the dogs was submitted to intravitreal uveal ablation, through vitreous chamber injection of 0,5ml of gentamicin sulfate solution (40mg/ml) associated with 0,3ml of dexamethasone dissodic phosphate (4mg/ml). All dogs were evaluated across scores varying of 0 to 3, indicating absent, discreet, moderate and intense, respectively, to evaluation of following clinical signs: secretion, conjunctival hiperemy, corneal edema, quemosis, blepharospasms, hifema, neovascularization, pigmentation and pannus. Scores varying of 0 to 2, indicating normal, reduced and enlargement appetite was also utilized. Besides it were measure the weight and intraocular pressure (IOP) through applanation tonometry. All measurement and evaluations were made in the day of the procedure (M0), after 1 week (M1), four (M4) and eight weeks (M8). Twelve animals were also evaluated with 12 weeks follow-up (M12), 10 animals with 6 months (M24) and 5 animals with 1 year follow-up (M48). To compare the treatment effect between moments in each group, Friedman test was used, with 5% of significance level.

Results: With relation to clinical signs, it was significant improvement in conjunctival hiperemy on M0 (median 2,0-range 2,0; 3,0) in relation to M12 (1,0-0,5; 1,0), M24 (1,0-1,0; 2,0) and M48 (1,0-0,0; 1,5). It was too significant increase in corneal edema on M1 (1,0-0,0; 1,25) in relation to M12 (1,5-1,0; 2,5) and M24 (2,0-2,0; 3,0). Another studied clinical signs, weight and appetite didn't show significant differences between moments. The IOP significantly decrease on M0 (mean 48,462mmHg; SEM 4,041) in relation to all other moments, from M1 (12,846mmHg; 2,614) until M48 (8,8mmHg; 3,338).

Conclusions: The intravitreal uveal ablation in dogs with chronic glaucoma is an efficient procedure in IOP control that don't modify significantly the weight and appetite, thus don't cause excessive pain.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

J.L.V. Chiurciu

MAIN : Abstracts, Poster : Intravitreal Uveal Ablation with Gentamicin
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.


777 W. Covell Blvd., Davis, CA 95616


  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357